Drugs for Lip Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 54)
| # |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
| 1 |
|
Erlotinib |
Approved, Investigational |
Phase 3 |
|
183319-69-9, 183321-74-6 |
176870 |
|
Synonyms:
[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine
[6,7-Bis(2-methoxy-ethoxy)quinazoline-4-yl]-(3-ethynylphenyl)amine
11C Erlotinib
11C-Erlotinib
CP-358
CP-358,774
CP-358774
CP-35877401
CP-358774-01
ERLOTINIB
Erlotinib HCL
Erlotinib hydrochloride
Erlotinibum
|
HCL, Erlotinib
Hydrochloride, erlotinib
N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine
NSC 718781
NSC 718781|OSI 744|OSI-774|R 1415|Tarceva®
OSI 744
OSI 774
OSI-774
R 1415
R-1415
RG-1415
RO-508231
Tarceva
|
|
| 2 |
|
Durvalumab |
Approved, Investigational |
Phase 2, Phase 3 |
|
1428935-60-7 |
|
|
Synonyms:
|
| 3 |
|
Cetuximab |
Approved |
Phase 2, Phase 3 |
|
205923-56-4 |
|
|
Synonyms:
ABP-494
ANTI EGFR
C225
C-225
C225|Erbitux®|IMC-225|IMC-C225
CETUXIMAB
Cétuximab
CETUXIMAB (GENETICAL RECOMBINATION)
|
Cetuximabum
CMAB009
CMAB-009
ERBITUX
IMC-225
IMC-C225
MOAB C225
|
|
| 4 |
|
Immunoglobulins |
|
Phase 2, Phase 3 |
|
|
|
| 5 |
|
Antibodies |
|
Phase 2, Phase 3 |
|
|
|
| 6 |
|
Antineoplastic Agents, Immunological |
|
Phase 2, Phase 3 |
|
|
|
| 7 |
|
Immunoglobulins, Intravenous |
|
Phase 2, Phase 3 |
|
|
|
| 8 |
|
Immunoglobulin G |
|
Phase 2, Phase 3 |
|
|
|
| 9 |
|
Antibodies, Monoclonal |
|
Phase 2, Phase 3 |
|
|
|
| 10 |
|
Aminolevulinic acid |
Approved |
Phase 1, Phase 2 |
|
106-60-5 |
137 |
|
Synonyms:
5 Aminolaevulinate
5 Aminolevulinate
5-ALA
5-Amino-4-oxopentanoate
5-Amino-4-oxo-pentanoate
5-Amino-4-oxopentanoic acid
5-Amino-4-oxo-pentanoic acid
5-Amino-4-oxovalerate
5-Amino-4-oxovaleric acid
5-Aminolaevulinate
5-Aminolaevulinic acid
5-Aminolevulinate
5-Amino-levulinate
5-Aminolevulinic acid
5-Amino-levulinic acid
Acid hydrochloride, aminolevulinic
Acid, aminolevulinic
Acid, Delta-aminolevulinic
|
ácido 5-aminolevulínico
Aladerm
Aminolevulinate
Aminolevulinic acid
Amino-levulinic acid
Aminolevulinic acid hydrochloride
Bertek brand OF aminolevulinic acid hydrochloride
dALA
Delta Aminolevulinic acid
delta-ALA
delta-Aminolevulinate
delta-Aminolevulinic acid
Hydrochloride, aminolevulinic acid
Kerastick
Levulan
δ-ALA
Δ-aminolevulinate
δ-aminolevulinic acid
|
|
| 11 |
|
Orange |
Approved |
Phase 1, Phase 2 |
|
|
|
| 12 |
|
Nivolumab |
Approved |
Phase 2 |
|
946414-94-4 |
|
|
Synonyms:
BMS-936558
BMS-936558|MDX-1106|ONO-4538|Opdivo®
MDX-1106
|
NIVOLUMAB
ONO-4538
OPDIVO
|
|
| 13 |
|
Cemiplimab |
Approved, Investigational |
Phase 2 |
|
1801342-60-8 |
|
|
Synonyms:
CEMIPLIMAB
CEMIPLIMAB-RWLC
cemiplimab-rwlc|Libtayo®|REGN-2810|REGN2810|SAR-439684|SAR439684
|
LIBTAYO
REGN2810
REGN-2810
|
|
| 14 |
|
Carboplatin |
Approved |
Phase 2 |
|
41575-94-4 |
10339178 38904 |
|
Synonyms:
Blastocarb
Carboplat
CARBOPLATIN
Carboplatine
Carboplatino
Carbosin
Carbotec
Cbdca
CIS-(1,1-CYCLOBUTANEDICARBOXYLATO)DIAMMINEPLATINUM(II)
CIS-DIAMMINE(1,1-CYCLOBUTANEDICARBOXYLATO)PLATINUM
CIS-DIAMMINE(1,1-CYCLOBUTANEDICARBOXYLATO)PLATINUM(II)
|
Ercar
JM 8
JM8
JM-8
Nealorin
Neocarbo
NSC-201345
NSC-241240
PARAPLATIN
Paraplatin-AQ
Ribocarbo
|
|
| 15 |
|
Paclitaxel |
Approved, Vet_approved |
Phase 2 |
|
33069-62-4 |
36314 |
|
Synonyms:
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5Β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5Β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7 Epi taxol
7-Epipaclitaxel
7-Epi-paclitaxel
7-epipaclitaxel|Abraxane® (albumin-bound suspension)|Taxol®
7-Epitaxol
7-Epi-taxol
ABI-007
ABRAXANE
Anzatax
BMS 181339-01
BMS-181339-01
Bris taxol
CAPXOL
CYCLOPAX
DHP 107
|
EBETAXEL
Epitaxol
GENETAXYL
GENEXOL
INTAXEL
LIPOPAC
MBT 0206
MITOTAX
NK 105
NSC-125973
Onxol
PACITAXEL
PACLITAXEL
Paclitaxel, (4 alpha)-isomer
Paxceed
Paxene
PLAXICEL
Praxel
QW-8184
TAXALBIN
TAXOL
TAXOL 100
Taxol a
Taxol, bris
Vascular Wrap
Xorane
YEWTAXAN
|
|
| 16 |
|
Photosensitizing Agents |
|
Phase 1, Phase 2 |
|
|
|
| 17 |
|
Dermatologic Agents |
|
Phase 1, Phase 2 |
|
|
|
| 18 |
|
Immune Checkpoint Inhibitors |
|
Phase 2 |
|
|
|
| 19 |
|
Mitogens |
|
Phase 1, Phase 2 |
|
|
|
| 20 |
|
Albumin-Bound Paclitaxel |
|
Phase 2 |
|
|
|
| 21 |
|
Antimitotic Agents |
|
Phase 2 |
|
|
|
| 22 |
|
Tubulin Modulators |
|
Phase 2 |
|
|
|
| 23 |
|
Anti-Infective Agents |
|
Phase 2 |
|
|
|
| 24 |
|
Anti-Bacterial Agents |
|
Phase 2 |
|
|
|
| 25 |
|
Antidotes |
|
Phase 2 |
|
|
|
| 26 |
|
Sodium thiosulfate |
|
Phase 2 |
|
|
|
|
Synonyms:
Anhydrous sodium thiosulfate
Anhydrous sodium thiosulfuric acid
Anhydrous sodium thiosulphate
Anhydrous sodium thiosulphuric acid
Disodium thiosulfate
Disodium thiosulfuric acid
Disodium thiosulphate
Disodium thiosulphuric acid
Pentahydrate OF sodium thiosulfate
Sodium hyposulfite
Sodium hyposulphite
Sodium oxide sulfide
Sodium oxide sulphide
|
Sodium thiosulfate (anhydrous)
Sodium thiosulfate anhydrous
Sodium thiosulfate pentahydrate
Sodium thiosulfuric acid
Sodium thiosulfuric acid (anhydrous)
Sodium thiosulphate
Sodium thiosulphate (anhydrous)
Sodium thiosulphuric acid
Sodium thiosulphuric acid (anhydrous)
Thiosulfate, disodium salt
Thiosulfuric acid, disodium salt
Thiosulphate, disodium salt
Thiosulphuric acid, disodium salt
|
|
| 27 |
|
Antitubercular Agents |
|
Phase 2 |
|
|
|
| 28 |
|
Antioxidants |
|
Phase 2 |
|
|
|
| 29 |
|
Protective Agents |
|
Phase 2 |
|
|
|
| 30 |
|
Chelating Agents |
|
Phase 2 |
|
|
|
| 31 |
|
Gemcitabine |
Approved |
Phase 1 |
|
95058-81-4, 122111-03-9 |
60750 |
|
Synonyms:
2',2'-DFDC
2',2'-Difluoro-2'-deoxycytidine
2',2'-Difluorodeoxycytidine
2'-Deoxy-2',2'-difluorocytidine
2'-Deoxy-2',2''-difluorocytidine-5'-O-monophosphate
2'-Deoxy-2'-difluorocytidine
4-Amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
DDFC
DFDC
DFdCyd
Gemcin
GEMCITABIN
Gemcitabina
Gemcitabina [INN-Spanish]
GEMCITABINE
GEMCITABINE HCL
|
Gemcitabine hydrochloride
gemcitabine hydrochloride|Gemzar®
Gemcitabine, (alpha-D-threo-pentofuranosyl)-isomer
Gemcitabine, (beta-D-threo-pentafuranosyl)-isomer
Gemcitabine, (D-threo-pentafuranosyl)-isomer
Gemcitabinum
Gemcitabinum [INN-Latin]
Gemtro
Gemzar
GEO
INFUGEM
LY188011
LY-188011
LY188011 HYDROCHLORIDE
LY-188011 HYDROCHLORIDE
NSC-613327
|
|
| 32 |
|
Pembrolizumab |
Approved |
Phase 1 |
|
1374853-91-4 |
254741536 |
|
Synonyms:
KEYLYNK-010 COMPONENT PEMBROLIZUMAB
KEYTRUDA
Keytruda®|lambrolizumab|MK-3475
LAMBROLIZUMAB
|
MK-3475
PEMBROLIZUMAB
PEMBROLIZUMAB COMPONENT OF KEYLYNK-010
SCH-900475
|
|
| 33 |
|
Doxycycline |
Approved, Investigational, Vet_approved |
Phase 1 |
|
564-25-0 |
54671203 |
|
Synonyms:
(4S,4AR,5S,5ar,6R,12as)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
5-Hydroxy-a-6-deoxytetracycline
5-Hydroxy-alpha-6-deoxytetracycline
5-Hydroxy-α-6-deoxytetracycline
6a-Deoxy-5-oxytetracycline
6-alpha-deoxy-5-oxytetracycline
6alpha-Deoxy-5-oxytetracycline
6Α-deoxy-5-oxytetracycline
Anhydrous doxycycline
BMY-28689|Monodox®|Vibramycin®
Doxcycline anhydrous
Doxiciclina
DOXY
Doxychel
Doxycyclin
Doxycycline
|
Doxycycline (anhydrous)
DOXYCYCLINE ANHYDROUS
DOXYCYCLINE HCL
Doxycycline hyclate
Doxycycline hydrate
Doxycycline hydric acid
Doxycycline monohydrate
Doxycycline monohydric acid
Doxycyclinum
Doxytetracycline
GS-3065
Jenacyclin
Monodox
Oracea
Supracyclin
Vibramycin
|
|
| 34 |
|
Cisplatin |
Approved |
Phase 1 |
|
15663-27-1 |
2767 5702198 441203 |
|
Synonyms:
Abiplatin
Biocisplatinum
Briplatin
CACP
Carboquone
CDDP
Cis Pt II
cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
CIS-DIAMMINEDICHLOROPLATINUM(II)
Cismaplat
CISPLATIN
Cisplatine
cisplatino
CISPLATINUM
CIS-PLATINUM II
Cisplatyl
Citoplationo
CPDC
CPDD
DDP
DDPT
|
Diamminedichloroplatinum
INT230-6 COMPONENT CISPLATIN
INT-230-6 COMPONENT CISPLATIN
Lederplatin
Neoplatin
NSC-119875
Plastin
Platamine
Platiblastin
Platidiam
Platinex
PLATINOL
PLATINOL-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
|
|
| 35 |
|
Nedisertib |
Investigational |
Phase 1 |
|
1637542-33-6 |
86292849 |
|
Synonyms:
example 136 [WO2014183850]|M3814|MSC2490484A|nedisertib (deleted INN)
M3814
M-3814
MSC 2490484A
|
MSC2490484A
MSC-2490484A
NEDISERTIB
|
|
| 36 |
|
Antiviral Agents |
|
Phase 1 |
|
|
|
| 37 |
|
Pharmaceutical Solutions |
|
Phase 1 |
|
|
|
| 38 |
|
Antiprotozoal Agents |
|
Phase 1 |
|
|
|
| 39 |
|
Antiparasitic Agents |
|
Phase 1 |
|
|
|
| 40 |
|
Antimalarials |
|
Phase 1 |
|
|
|
| 41 |
|
Nicotine |
Approved |
|
|
54-11-5 |
942 89594 |
|
Synonyms:
(-)-3-(1-Methyl-2-pyrrolidyl)pyridine
(-)-3-(N-Methylpyrrolidino)pyridine
(−)-nicotine
(-)-Nicotine
(+-)-3-(1-Methyl-2-pyrrolidinyl)pyridine
(+)-Nicotine
(+-)-Nicotine
(R)-3-(1-Methyl-2-pyrrolidinyl)pyridine
(R,S)-Nicotine
(RS)-Nicotine
(S)-(−)-nicotine
(S)-(-)-Nicotine
(S)-3-(1-Methylpyrrolidin-2-yl)pyridine
(S)-3-(N-Methylpyrrolidin-2-yl)pyridine
(S)-Nicotine
1-Methyl-2-(3-pyridal)-pyrrolidene
1-Methyl-2-(3-pyridal)-pyrrolidine
1-Methyl-2-(3-pyridiyl)pyrrolidine
1-Methyl-2-(3-pyridyl)pyrrolidine
2'-beta-H-Nicotine
3-(1-Methyl-2-pyrollidinyl)pyridine
3-(1-Methyl-2-pyrrolidinyl)pyridine
3-(1-Methyl-2-pyrrolidinyl)-pyridine
3-(1-Methylpyrrolidin-2-yl)pyridine
3-(2-(N-Methylpyrrolidinyl))pyridine
3-(N-Methylpyrollidino)pyridine
3-(N-Methylpyrrolidino)pyridine
3-N-Methylpyrrolidine
a -N-Methylpyrrolidine
alpha-N-Methylpyrrolidine
a-N-Methylpyrrolidine
beta-Pyridyl-alpha-N-methylpyrrolidine
Bitartrate, nicotine
Black Leaf
Black Leaf 40
Campbell's Nico-Soap
Commit
delta-Nicotine
Destruxol
Destruxol Orchid Spray
DL-Tetrahydronicotyrine
D-Nicotine
Emo-Nik
Flux Maag
Fumeto bac
Fumetobac
Habitrol
L(−)-nicotine
L(-)-Nicotine
L-3-(1-Methyl-2-pyrrolidyl)pyridine
L-Nicotine
|
Mach-Nic
Methyl-2-pyrrolidinyl)pyridine
Niagara P.A. Dust
NICABATE
Nicocide
Nicoderm
NICODERM CQ
Nico-Dust
Nico-Fume
NICOPASS
NICOPATCH
Nicorette
NICORETTE INVISI
Nicorette Plus
Nicorette®|Nicotrol®
Nicotin
Nicotina
Nicotine
Nicotine alkaloid
Nicotine betadex
Nicotine bitartrate
Nicotine polacrilex
Nicotine tartrate
NICOTINELL CLASSIC
NICOTINELL SUPPORT
NICOTINELL TTS 10
NICOTINELL TTS 20
NICOTINELL TTS 30
NICOTROL
NICOTROL INHALER
NICOTROL NS
Nic-Sal
Nikotin
Nikotyna
NIQUITIN
NIQUITIN CLR
NIQUITIN MINIS CHERRY
NIQUITIN MINIS MINT
NIQUITIN MINIS ORANGE
NIQUITIN MINT
NIQUITIN PRE-QUIT
NIQUITIN STRIPS MINT
Ortho N-4 Dust
Ortho N-5 Dust
PROSTEP
R)-(+)-Nicotine
STOPPERS
STUBIT
Tartrate, nicotine
Tendust
|
|
| 42 |
|
Imiquimod |
Approved, Investigational |
Early Phase 1 |
|
99011-02-6 |
57469 |
|
Synonyms:
1-Isobutyl-1H-imidazo(4,5-c)quinolin-4-amine
1-Isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
4-Amino-1-isobutyl-1H-imidazo(4,5-c)quinoline
Aldara
Aldara®|R837|S-26308|Zyclara®
Imiquimod
Imiquimod acetate
|
Imiquimodum
R 837
R-837
S-26308
ZARTRA
Zyclara
|
|
| 43 |
|
Ethanol |
Approved |
|
|
64-17-5 |
702 |
|
Synonyms:
[CH2Me(OH)]
[OEtH]
1-Hydroxyethane
ABLYSINOL
Absolute alcohol
Absolute ethanol
Absolute ethyl alcohol
Aethanol
Aethylalkohol
Alcare hand degermer
Alcohol
Alcohol (ethyl)
Alcohol anhydrous
Alcohol denatured
ALCOHOL DETERMINATION--ALCOHOL
Alcohol etilico
Alcohol etílico
Alcohol, absolute
Alcohol, Dehydrated
Alcohol, denatured
ALCOHOL, DILUTED
Alcohol, ethyl
Alcohol, grain
ALCOHOL, RUBBING
Alcohols
Alcool ethylique
Alcool éthylique
Alcool etilico
Algrain
Alkohol
Alkoholu etylowego
Aminoethanol
Anhydrol
Anhydrous alcohol
Anhydrous ethanol
Äthanol
Äthylalkohol
B3324
Beta-Aminoethanol
Beta-Aminoethyl Alcohol
Beta-Ethanolamine
Beta-Hydroxyethylamine
C2H5OH
Caswell No. 426
Colamine
Cologne spirit
Cologne spirits
Dehydrated alcohol
Dehydrated ethanol
Denatured alcohol
Denatured Alcohol Cd-10
Denatured Alcohol Cd-5
Denatured Alcohol Cd-5a
Denatured Alcohol Sd-1
Denatured Alcohol Sd-13a
Denatured Alcohol Sd-17
Denatured Alcohol Sd-23a
Denatured Alcohol Sd-28
Denatured Alcohol Sd-30
Denatured Alcohol Sd-39b
Denatured Alcohol Sd-39c
Denatured Alcohol Sd-3a
Denatured Alcohol Sd-40m
Denatured ethanol
Desinfektol el
Diluted alcohol
Distilled spirits
DRINKING ALCOHOL
E1510
Envision Conditioner Pdd 9020
ETA
Etanol
|
Etanolo
ETHANOL
éthanol
Ethanol 200 proof
Ethanol Absolute
Ethanol Absolute Bp
Ethanol Anhydrous
Ethanol Extra Pure
Ethanol solution
Ethanol, Silent Spirit
Ethicap
Ethyl alc
Ethyl alcohol
Ethyl Alcohol & Water, 10%
Ethyl Alcohol & Water, 20%
Ethyl Alcohol & Water, 30%
Ethyl Alcohol & Water, 40%
Ethyl Alcohol & Water, 5%
Ethyl Alcohol & Water, 50%
Ethyl Alcohol & Water, 60%
Ethyl Alcohol & Water, 70%
Ethyl Alcohol & Water, 80%
Ethyl Alcohol & Water, 95%
Ethyl Alcohol & Water, 96%
Ethyl alcohol anhydrous
Ethyl alcohol in alcoholic beverages
Ethyl alcohol usp
Ethyl Alcohol, Anhydrous
Ethyl Alcohol, Denatured
Ethyl hydrate
Ethyl hydroxide
Ethylol
Ethylolamine
EtOH
FEMA NO. 2419
Fermentation alcohol
Glycinol
Grain alcohol
Hinetoless
HSDB 531
Hydroxyethane
Infinity pure
Jaysol
Jaysol S
Lux
METHYLATED MINERAL
Methylated Spirit Mineralised
Methylcarbinol
Molasses alcohol
NCI-C03134
NSC-85228
PM-6193-200
Potato alcohol
Punctilious ethyl alcohol
Pyro
Reagent Alcohol
Silent spirit
SPIRIGEL
Spirit
Spirits OF wine
Spiritus vini
Spirt
SURG
Synasol
Tecsol
Tecsol C
Thanol
Thiofaco M-50
Undenatured ethanol
USAF EK-1597
VODKA
|
|
| 44 |
|
Heparin, bovine |
Approved, Investigational, Withdrawn |
Early Phase 1 |
|
9005-49-6 |
22833565 9812414 772 |
|
Synonyms:
Adomiparin
alpha-Heparin
Ariven
Arteven
Bemiparin
BOVINE HEPARIN
Calcilean
CALCIPARINE
Certoparin
CLEXANE
Clexane®|enoxaparin sodium|Lovenox®|PK-10169|RP-54563
Clivarin
Clivarine
DALTEPARIININATRIUM
Dalteparin
DALTEPARIN SODIUM
dalteparin sodium|Fragmin®
DALTEPARIN SODNÁ SŮL
DALTEPARIN SODYUM
DALTEPARINA SODICA
DALTEPARINA SÓDICA
DALTEPARINE SODIQUE
DALTÉPARINE SODIQUE
DALTEPARINNATRIUM
DALTEPARIN-NATRIUM
DALTEPARIN-NÁTRIUM
DALTEPARINO NATRIO DRUSKA
DALTEPARINUM NATRICUM
DALTEPARYNA SODOWA
Depo-Heparin
ENOXAPARIN
ENOXAPARIN SODIUM
ENOXAPARIN SODIUM (PRESERVATIVE FREE)
ENOXAPARIN SODIUM SALT
Eparina
Eparina [DCIT]
Fluxum
FR-860
FRAGMIN
Fragmin A
Fragmin B
Fraxiparin
Hed-Heparin
Hepalean
HEPARIN
Heparin Cy 216
|
HEPARIN FRAGMENT KABI 2165
Heparin Leo
Heparin Lock Flush
HEPARIN SODIUM
Heparin sodium preservative Free
Heparin sodium salt
Heparin sulfate
Heparin sulphate
Heparina
HEPARINATE
Heparine
HEPARINIC ACID
Heparinsodiumsalt
Heparinum
Hepathrom
HepFlush®
HEP-LOCK
KABI-2165
Leparan
Lipo-Hepin
LIQUAEMIN
Liquaemin Sodium
Liquemin
LOVENOX
LOVENOX (PRESERVATIVE FREE)
LOW LIQUEMINE
Low molecular weight heparin sodium
Multiparin
Novoheparin
Pabyrin
PANHEPRIN
Parnaparin
Parnaparin sodium
Parvoparin
PK-10169
Pularin
Reviparin
RP-54563
Sandoparin
SODIUM HEPARIN
Sublingula
TEDELPARIN
Thromboliquine
Unfractionated heparin
Vetren
Vitrum AB
|
|
| 45 |
|
Anesthetics |
|
|
|
|
|
| 46 |
|
Endothelial Growth Factors |
|
|
|
|
|
| 47 |
|
Tea |
|
|
|
|
|
| 48 |
|
Adjuvants, Immunologic |
|
Early Phase 1 |
|
|
|
| 49 |
|
interferons |
|
Early Phase 1 |
|
|
|
| 50 |
|
Anti-Inflammatory Agents |
|
Early Phase 1 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 59)
| # |
Name |
Status |
NCT ID |
Phase |
Drugs |
| 1 |
The Optimal Neck Treatments Strategy of Early Oral Cancer Based on Adverse Pathological Factor |
Recruiting |
NCT03017053 |
Phase 4 |
|
| 2 |
Comparing the Test Characteristics of Three Oral Cancer Screening Techniques:1)Unaided Visual Examination 2)VelScope Examination and 3)Toluidine Blue Application, by Trained Primary Health Care Workers in Mumbai, India. |
Unknown status |
NCT00655421 |
Phase 3 |
|
| 3 |
Canadian Optically Guided Approach for Oral Lesions Surgical Trial - COOLS |
Unknown status |
NCT01039298 |
Phase 3 |
|
| 4 |
Workplace Tobacco Cessation And Oral Cancer Screening Study |
Completed |
NCT00750503 |
Phase 3 |
|
| 5 |
Erlotinib Prevention of Oral Cancer (EPOC) |
Completed |
NCT00402779 |
Phase 3 |
Erlotinib;Placebo |
| 6 |
Randomized Phase II/III Trial of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Early-Stage Oral Cavity Cancer |
Recruiting |
NCT04333537 |
Phase 2, Phase 3 |
Imaging Agent |
| 7 |
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin |
Active, not recruiting |
NCT03258554 |
Phase 2, Phase 3 |
|
| 8 |
Low-cost Enabling Technology for Image-guided Photodynamic Therapy (PDT) of Oral |
Completed |
NCT03638622 |
Phase 1, Phase 2 |
|
| 9 |
Clinical Protocol for Wild Type p53 Gene Induction in Premalignancies of Squamous Epithelium of the Oral Cavity and Oral Pharynx Via an Adenoviral Vector [NCI Supplied Agent Ad-p53, (INGN 201) (Advexin®) NSC 683550, IND# 7135] |
Completed |
NCT00064103 |
Phase 1, Phase 2 |
|
| 10 |
Phase II Trial of Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer |
Completed |
NCT03258008 |
Phase 2 |
Utomilumab |
| 11 |
Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing |
Recruiting |
NCT02734537 |
Phase 2 |
Cisplatin |
| 12 |
Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Patients With Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study |
Recruiting |
NCT05136196 |
Phase 2 |
Cabozantinib S-malate |
| 13 |
Bayesian Phase II Trial of Magnetic Resonance Imaging Guided Radiotherapy Dose Adaptation in Human Papilloma Virus Positive Oropharyngeal Cancer |
Recruiting |
NCT03224000 |
Phase 2 |
|
| 14 |
A Phase II Trial of the Efficacy and Safety of the Combination of Cemiplimab and Low-Dose Paclitaxel and Carboplatin in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck |
Recruiting |
NCT04862650 |
Phase 2 |
Carboplatin;Paclitaxel |
| 15 |
A Phase I-II, FIH Study of A166 in Locally Advanced/Metastatic Solid Tumors Expressing Human Epidermal Growth Factor Receptor 2 (HER2) or Are HER2 Amplified That Did Not Respond or Stopped Responding to Approved Therapies |
Active, not recruiting |
NCT03602079 |
Phase 1, Phase 2 |
A166 |
| 16 |
Multimodality Therapy With Induction Carboplatin/Nab-Paclitaxel/Durvalumab Followed by Surgical Resection and Risk-adapted Adjuvant Therapy for the Treatment of Locally-Advanced and Surgically Resectable Squamous Cell Carcinoma of the Head and Neck |
Active, not recruiting |
NCT03174275 |
Phase 2 |
Durvalumab;Carboplatin;Nab-paclitaxel;Cisplatin |
| 17 |
A Phase II Study of Sodium Thiosulfate (STS) for Prevention of Ototoxicity in Patients With Locally Advanced Squamous Cell Carcinoma of Head and Neck (SCCHN) Undergoing Concurrent Chemoradiation With Cisplatin |
Active, not recruiting |
NCT04541355 |
Phase 2 |
Cisplatin;Sodium Thiosulfate |
| 18 |
Guided by Light: Optimizing Surgical Excision of Oral Cancer Using Real-time Fluorescence Imaging |
Not yet recruiting |
NCT04191460 |
Phase 2 |
cRGD-ZW800-1. |
| 19 |
Intraoperative Visualization of Oral Cavity Squamous Cell Carcinoma and High-Grade Dysplasia With Tozuleristide, a Fluorescent Tumor Marking Agent |
Not yet recruiting |
NCT05316688 |
Phase 1, Phase 2 |
Tozuleristide |
| 20 |
Phase I Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases |
Recruiting |
NCT03093909 |
Phase 1 |
Gemcitabine |
| 21 |
Phase I Trial of BAY 1895344 ATR Inhibitor Combined With Stereotactic Body Radiation Therapy and Pembrolizumab for Recurrent Head and Neck Squamous Cell Carcinoma |
Recruiting |
NCT04576091 |
Phase 1 |
Elimusertib |
| 22 |
Phase I/Ib Study of AKT Inhibitor Ipatasertib With Chemoradiation for Locally Advanced Head and Neck Cancer |
Recruiting |
NCT05172245 |
Phase 1 |
Cisplatin;Ipatasertib |
| 23 |
A Phase Ib Investigation of Pembrolizumab in Combination With Intratumoral Injection of Clostridium Novyi-NT in Patients With Treatment-Refractory Solid Tumors |
Recruiting |
NCT03435952 |
Phase 1 |
Pembrolizumab;Doxycycline |
| 24 |
Phase I Trial With Expansion Cohort of DNA-PK Inhibition and IMRT in Cisplatin-Ineligible Patients With Stage 3-4 Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC) |
Suspended |
NCT04533750 |
Phase 1 |
Peposertib |
| 25 |
Phase I Study of Intraarterial ONYX-015 in Combination With Intravenous Cisplatin and Fluorouracil in Patients With Advanced Squamous Cell Cancer of the Head and Neck |
Withdrawn |
NCT00006106 |
Phase 1 |
cisplatin;fluorouracil;ONYX-015 |
| 26 |
A Phase I Study of Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies |
Withdrawn |
NCT02812056 |
Phase 1 |
Alisertib;TAK-228 |
| 27 |
A Phase I Trial of Lenvatinib (Multi-kinase Inhibitor) and Capecitabine (Anti-metabolite) in Patients With Advanced Malignancies |
Withdrawn |
NCT02915172 |
Phase 1 |
Lenvatinib;Capecitabine |
| 28 |
Observational Study on the Carcinogenesis of Gα12 in Oral Cancer, and Chemopreventive Possibility for the Treatment of Oral Cancer Using Ga12 Inhibitor. |
Unknown status |
NCT01919580 |
|
|
| 29 |
Observational Study on the Carcinogenesis of SOX-9 in Oral Cancer, and Chemopreventive Possibility for the Treatment of Oral Cancer Using SOX-9 Inhibitor. |
Unknown status |
NCT01919567 |
|
|
| 30 |
Yeur-Hur Lai, PhD, RN, School of Nursing, College of Medicine, National Taiwan University |
Unknown status |
NCT04214912 |
|
|
| 31 |
The Role of Vascular Endothelial Growth Factor-C (VEGF-C) and Its Receptors Induced Lymphangiogenesis on the Carcinogenesis of Oral Cancers and Premalignant Lesions |
Unknown status |
NCT00173316 |
|
|
| 32 |
Dual-time PET/CT and Sentinel Node Diagnostics Preoperatively in Patients With Oral Cancer |
Unknown status |
NCT01136265 |
|
|
| 33 |
Dyadic Yoga Intervention for Patient With Head and Neck Cancer Undergoing Radiotherapy and Their Family Caregivers |
Unknown status |
NCT03114501 |
|
|
| 34 |
Oral State of Patients Affected by an Oral Cancer Before and After Radiotherapy - 3-years Prospective Study |
Unknown status |
NCT02866500 |
|
|
| 35 |
Validation of DNA Methylation Biomarkers for Oral Cancer Detection-Follow up Study |
Unknown status |
NCT02902406 |
|
|
| 36 |
Correlative Study of Nicotine Levels With Response Rates to Therapy Using Radiation Alone or in Combination With Chemotherapy in Head and Neck Cancer |
Completed |
NCT01084733 |
|
|
| 37 |
A Longitudinal Study of Plasma EBV DNA in Nasopharyngeal Carcinoma From Both Endemic and Non-Endemic Patient Populations |
Completed |
NCT00186433 |
|
|
| 38 |
Validation of DNA Methylation Biomarkers for Oral Cancer Detection |
Completed |
NCT01945697 |
|
|
| 39 |
Validation of DNA Methylation Biomarkers for Oral Cancer Detection |
Completed |
NCT02648789 |
|
|
| 40 |
Effectiveness of Green Tea Mouthwash on the Oral Health Status in Oral Cancer Patients: A Single-blind Randomized Clinical Trial and a CONSORT-compliant Article |
Completed |
NCT04615780 |
|
|
| 41 |
Retrospective Analysis Of Sensory Recovery Of Donor Size And Related Quality Life In Oral Cancer Patients Receiving Free Flap Reconstruction |
Completed |
NCT02048631 |
|
|
| 42 |
Rehabilitation Outcomes of Shoulder Function in Oral Cancer Survivors Cancer Survivors |
Completed |
NCT03545100 |
|
|
| 43 |
Epstein-Barr Detection in Squamous Cell Carcinoma and Healthy Oral Mucosa |
Completed |
NCT01039272 |
|
|
| 44 |
Clinical Evaluation of the OncAlert RAPID; Impact on Decision-Making |
Completed |
NCT03239834 |
|
|
| 45 |
Using an APP in Post Oral Cancer Surgery to Affect Patients' Needs and Quality of Life. |
Completed |
NCT04049968 |
|
|
| 46 |
Randomized Intervention Trial to Evaluate Oral Visual Inspection in the Control of Oral Cancer |
Completed |
NCT04494620 |
|
|
| 47 |
Web-based Education on Oral Cancer for Primary Care Physicians in Ohio |
Completed |
NCT01424358 |
|
|
| 48 |
Behavior Change on Oral Cancer Patients After a Localized Behavior Change Model Intervention |
Completed |
NCT01351532 |
|
|
| 49 |
Integrated Cancer Repository for Cancer Research |
Recruiting |
NCT02012699 |
|
|
| 50 |
Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers |
Recruiting |
NCT00568490 |
|
|
Cochrane evidence based reviews: lip neoplasms
|
